Pharmacology. Inamrinone is a positive inotropic agent with vasodilator activity. It is not a beta-adrenergic receptor agonist, and its exact mechanism of action is unknown. It appears to work by inhibiting myocardial cell phosphodiesterase activity, thereby increasing cellular concentrations of cyclic AMP. Cardiac afterload and preload are reduced owing to a direct vasodilator effect.

Indications. Inamrinone may be useful for patients with beta blocker, mixed beta and alpha blocker (eg, labetalol), or calcium antagonist overdose when intravenous fluids, atropine, beta agonists, glucagon, high-dose insulin with supplemental dextrose, and lipid emulsion therapy have failed to restore cardiac output and blood pressure.

Contraindications. Known hypersensitivity to inamrinone or sulfites (used as a preservative).

Related posts:

Anesthetics, Local Special Considerations in Pediatric Patients Anticonvulsants, Newer Emergency Evaluation and Treatment Beta2-Adrenergic Stimulants Copper

Stay updated, free articles. Join our Telegram channel

Join